Axitinib medical insurance reimbursement conditions and patient application process for medical insurance

Axitinib is a highly selective VEGFRtyrosine kinase inhibitor, mainly used to treat malignant tumors such as advanced renal cell carcinoma (RCC). With the official launch of the drug in China and the continuous improvement of medical insurance policies, axitinib has been included in the national medical insurance directory, allowing more patients to obtain treatment at a relatively reasonable price. At present, the price of domestically imported original drugs is about more than 4,000 yuan per box (specific specifications are subject to announcements in hospital pharmacies). After medical insurance reimbursement, the proportion of patients paying out of pocket has dropped significantly, greatly reducing the economic burden of long-term medication.

According to medical insurance policies, eligible patients can enjoy part or most of the reimbursement when using axitinib. Generally speaking, patients need to be diagnosed with a disease that meets the indications in the medical insurance catalog (such as renal cell cancer) before they can enjoy medical insurance benefits. The reimbursement ratio varies according to regional policies, medical insurance type (employee medical insurance or resident medical insurance) and hospital level. First-tier cities and large hospitals usually implement more complete reimbursement systems. Some areas can also enjoy "secondary reimbursement" or "outpatient chronic disease reimbursement" policies for special diseases or major diseases, further reducing personal burdens.

The process of applying for medical insurance reimbursement is usually relatively standardized. First, patients should purchase axitinib at a pharmacy or hospital pharmacy qualified for medical insurance settlement with the diagnosis certificate and prescription from a regular hospital; secondly, the prescribing doctor must indicate the drug name, dosage and course of treatment; then the patient can settle directly through the medical insurance system, or submit medical records, invoices and ID documents through offline reimbursement windows for manual review in some areas. For outpatients with special diseases or long-term medication, the attending doctor can submit a chronic disease registration application, and only after approval by the medical insurance department can they enjoy the long-term reimbursement policy.

In addition to domestic medical insurance channels, some patients will also pay attention to the overseas generic drug market. At present, the price of the Indian and Lao generic versions of axitinib is around a few hundred yuan, which is lower than the original drug. However, patients need to pay attention to the legality of the drug purchase route and the risks of drug quality. Overall, with the inclusion of axitinib in medical insurance and its popularity in the country, patient access to treatment has significantly improved. It is recommended that patients consult professional doctors and medical insurance departments before taking medication, and rationally choose drug purchase channels and reimbursement methods to ensure both efficacy and safety.

Reference materials:https://www.drugs.com/